Immuneering Appoints Harold E. Brakewood as Chief Business Officer
28 mars 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
14 mars 2023 16h30 HE
|
Immuneering Corporation
Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment Biomarker discovery and clinical translation supports patient selection in ongoing Phase 1/2a clinical...
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
06 mars 2023 16h05 HE
|
Immuneering Corporation
First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected...
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
05 mars 2023 18h30 HE
|
Immuneering Corporation
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid...
Immuneering Announces Participation in March Investor Conferences
28 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
27 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immuneering To Present at Guggenheim 2023 Oncology Conference
31 janv. 2023 06h50 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical stage biopharmaceutical company that aims to create medicines for all patients with solid...
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
28 nov. 2022 06h50 HE
|
Immuneering Corporation
IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date First patient dosed follows swiftly from IND clearance at the end of September CAMBRIDGE, Mass., Nov. ...
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
10 nov. 2022 09h00 HE
|
Immuneering Corporation
IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint Blockade IMM-6-415 is Designed to Provide Deep Cyclic Inhibition of the MAPK...
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
10 nov. 2022 09h00 HE
|
Immuneering Corporation
Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares...